


cobas® Influenza A/B

Timely diagnosis, effective patient management



Influenza affects 5-10% of adults and 20-30% of children each year.¹ The demands of the flu season require a fast and accurate diagnosis for effective clinical management and infection control.

The **cobas**® Influenza A/B Nucleic acid test for use on the **cobas**® Liat® System is a multiplex real-time polymerase chain reaction (PCR) test to detect influenza A and B in ~20 minutes. **cobas**® Influenza A/B can now also be used by healthcare providers in non-traditional testing sites, including emergency rooms, physician offices and other healthcare facilities.

Get the speed and reliability you need to support a timely, accurate diagnosis with the **cobas**® Influenza A/B test. Its lab-quality results provide the reassurance needed when prescribing antiviral treatment.

¹World Health Organization. Vaccines against influenza. WHO position paper – November 2012 Weekly Epidemiol Record 2012;87(47):461–76.

cobas® Influenza A/B offers:

Lab-quality performance in the detection and differentiation of Influenza A and Influenza B

Fast results with a 20 minute turn-around-time

Simple to use with minimal hands-on-time, easy interpretation of results

Roche PCR sensitivity supports confident treatment decisions


cobas® Influenza A/B performance*

	Sensitivity	Specificity	LOD
Influenza A	97.5%	97.9%**	10 ⁻² -10 ⁻¹ TCID ₅₀ /mL
Influenza B	96.9%	97.9%**	10 ⁻³ -10 ⁻¹ TCID ₅₀ /mL

*Compared to viral culture

Influenza A: Of 15 **cobas® Liat® System positive, culture negative specimens, 9 were positive and 6 were negative by PCR/sequencing. Two **cobas**® Liat® System negative, culture positive specimens were positive by PCR/sequencing. Influenza B: Of 16 **cobas**® Liat® System positive, culture negative specimens, 14 were positive and 2 were negative by PCR/sequencing. One **cobas**® Liat® System negative, culture positive specimen was positive by PCR/sequencing and was negative by lab-based RT-PCR.

Example of a patient impact workflow



*RIDT=rapid influenza diagnostic test



From patient sample to definitive results

The **cobas**® Liat® System enables you to run advanced PCR diagnostic tests with speed and simplicity.

Sample



Add your patient sample to the **cobas**® Liat® assay tube with provided transfer pipette.

Scan



Scan assay tube using built-in barcode reader.

Start



Insert assay tube into the **cobas**® Liat® Analyzer.

Patient sample to definitive results, in 20 minutes or less

cobas® Influenza A/B specifications

Instrument	cobas ® Liat® Analyzer
Targets	Influenza A Influenza B
Sample type	Nasopharyngeal swab
Collection media	Universal Transport Media (UTM)
Sample extraction	Fully automated and integrated
Technology	Real-time RT-PCR
Control	Internal sample processing control, positive and negative controls
Time to result	20 minutes
Reagents	Ready-to-use, pre-packed tube format
Kit storage	2-8°C
Registration	CE-IVD and FDA 510(k) cleared; CLIA waived

cobas® Influenza A/B ordering information

Material number	Description	Qty per unit
08278237702	cobas ® Influenza A/B <ul style="list-style-type: none"> ▪ 07341890190 cobas® Influenza A/B Test ▪ 07806108190 cobas® Influenza A/B Package Insert 	20 tests
08278245702	cobas ® Influenza A/B Quality Control Kit <ul style="list-style-type: none"> ▪ 07402660190 cobas® Influenza A/B Quality Control Kit ▪ 07806116190 cobas® Influenza A/B Quality Control Kit Package Insert 	3 sets

Material number	System
07341920190	cobas ® Liat® Analyzer

The **cobas**® Liat® System is available in select markets.

COBAS and LIAT are trademarks of Roche.
All other trademarks are the property of their respective owners.

© 2017 Roche

Roche Molecular Systems, Inc.
4300 Hacienda Drive
Pleasanton, CA 94588
USA

www.molecular.roche.com www.cobasliat.com

PP-GBL-00133 ① 0317

